company background image

Ipsen ENXTPA:IPN Stock Report

Last Price


Market Cap







25 May, 2022


Company Financials +
IPN fundamental analysis
Snowflake Score
Future Growth1/6
Past Performance6/6
Financial Health5/6

IPN Stock Overview

Ipsen S.A. operates as a biopharmaceutical company worldwide.

Ipsen Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ipsen
Historical stock prices
Current Share Price€96.45
52 Week High€121.00
52 Week Low€77.00
1 Month Change-12.16%
3 Month Change-5.44%
1 Year Change12.60%
3 Year Change-11.43%
5 Year Change-14.08%
Change since IPO306.96%

Recent News & Updates

May 04
Ipsen (EPA:IPN) Is Increasing Its Dividend To €1.20

Ipsen (EPA:IPN) Is Increasing Its Dividend To €1.20

Ipsen S.A.'s ( EPA:IPN ) dividend will be increasing to €1.20 on 2nd of June. Despite this raise, the dividend yield of...

Shareholder Returns

IPNFR PharmaceuticalsFR Market

Return vs Industry: IPN underperformed the French Pharmaceuticals industry which returned 17.6% over the past year.

Return vs Market: IPN exceeded the French Market which returned -6.3% over the past year.

Price Volatility

Is IPN's price volatile compared to industry and market?
IPN volatility
IPN Average Weekly Movement5.0%
Pharmaceuticals Industry Average Movement5.3%
Market Average Movement6.0%
10% most volatile stocks in FR Market10.1%
10% least volatile stocks in FR Market3.5%

Stable Share Price: IPN is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: IPN's weekly volatility (5%) has been stable over the past year.

About the Company

19295,744David Loew

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents.

Ipsen Fundamentals Summary

How do Ipsen's earnings and revenue compare to its market cap?
IPN fundamental statistics
Market Cap€7.96b
Earnings (TTM)€646.60m
Revenue (TTM)€3.00b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IPN income statement (TTM)
Cost of Revenue€538.00m
Gross Profit€2.46b
Other Expenses€1.81b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Jul 28, 2022

Earnings per share (EPS)7.84
Gross Margin82.06%
Net Profit Margin21.56%
Debt/Equity Ratio29.6%

How did IPN perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio

Does IPN pay a reliable dividends?

See IPN dividend history and benchmarks
When do you need to buy IPN by to receive an upcoming dividend?
Ipsen dividend dates
Ex Dividend DateMay 31 2022
Dividend Pay DateJun 02 2022
Days until Ex dividend5 days
Days until Dividend pay date7 days

Does IPN pay a reliable dividends?

See IPN dividend history and benchmarks


Is Ipsen undervalued compared to its fair value and its price relative to the market?

Valuation Score


Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: IPN (€96.45) is trading below our estimate of fair value (€224.48)

Significantly Below Fair Value: IPN is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: IPN is good value based on its Price-To-Earnings Ratio (12.3x) compared to the French Pharmaceuticals industry average (23.5x).

PE vs Market: IPN is good value based on its Price-To-Earnings Ratio (12.3x) compared to the French market (16.1x).

Price to Earnings Growth Ratio

PEG Ratio: IPN is poor value based on its PEG Ratio (13.6x)

Price to Book Ratio

PB vs Industry: IPN is overvalued based on its Price-To-Book Ratio (2.9x) compared to the FR Pharmaceuticals industry average (2.4x).

Future Growth

How is Ipsen forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?

Future Growth Score


Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IPN's forecast earnings growth (0.9% per year) is above the savings rate (0.3%).

Earnings vs Market: IPN's earnings (0.9% per year) are forecast to grow slower than the French market (11.9% per year).

High Growth Earnings: IPN's earnings are forecast to grow, but not significantly.

Revenue vs Market: IPN's revenue (1.1% per year) is forecast to grow slower than the French market (5.8% per year).

High Growth Revenue: IPN's revenue (1.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: IPN's Return on Equity is forecast to be low in 3 years time (16.6%).

Past Performance

How has Ipsen performed over the past 5 years?

Past Performance Score


Past Performance Score 6/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: IPN has high quality earnings.

Growing Profit Margin: IPN's current net profit margins (21.6%) are higher than last year (20.4%).

Past Earnings Growth Analysis

Earnings Trend: IPN's earnings have grown by 17.2% per year over the past 5 years.

Accelerating Growth: IPN's earnings growth over the past year (18%) exceeds its 5-year average (17.2% per year).

Earnings vs Industry: IPN earnings growth over the past year (18%) exceeded the Pharmaceuticals industry 9%.

Return on Equity

High ROE: IPN's Return on Equity (23.5%) is considered high.

Financial Health

How is Ipsen's financial position?

Financial Health Score


Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: IPN's short term assets (€2.0B) exceed its short term liabilities (€1.2B).

Long Term Liabilities: IPN's short term assets (€2.0B) exceed its long term liabilities (€1.0B).

Debt to Equity History and Analysis

Debt Level: IPN's net debt to equity ratio (0.05%) is considered satisfactory.

Reducing Debt: IPN's debt to equity ratio has increased from 26.6% to 29.6% over the past 5 years.

Debt Coverage: IPN's debt is well covered by operating cash flow (111.4%).

Interest Coverage: IPN's interest payments on its debt are well covered by EBIT (43x coverage).

Balance Sheet


What is Ipsen current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 4/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


Current Dividend Yield

Upcoming Dividend Payment

TodayMay 25 2022Ex Dividend DateMay 31 2022Dividend Pay DateJun 02 20222 days from Ex DividendBuy in the next 5 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: IPN's dividend (1.24%) isn’t notable compared to the bottom 25% of dividend payers in the French market (1.72%).

High Dividend: IPN's dividend (1.24%) is low compared to the top 25% of dividend payers in the French market (5.04%).

Stability and Growth of Payments

Stable Dividend: IPN's dividends per share have been stable in the past 10 years.

Growing Dividend: IPN's dividend payments have increased over the past 10 years.

Earnings Payout to Shareholders

Earnings Coverage: With its low payout ratio (15.3%), IPN's dividend payments are well covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its low cash payout ratio (20.6%), IPN's dividend payments are well covered by cash flows.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


David Loew (54 yo)





Mr. David Loew has been the Chief Executive Officer & MD of Ipsen S.A. since July 1, 2020, and serves as its Director since May 28, 2020. Mr. Loew served as an Executive Vice President of Sanofi Pasteur at...

CEO Compensation Analysis

Compensation vs Market: David's total compensation ($USD5.16M) is above average for companies of similar size in the French market ($USD2.57M).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: IPN's management team is considered experienced (4.3 years average tenure).

Board Members

Experienced Board: IPN's board of directors are seasoned and experienced ( 10.1 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Ipsen S.A.'s employee growth, exchange listings and data sources

Key Information

  • Name: Ipsen S.A.
  • Ticker: IPN
  • Exchange: ENXTPA
  • Founded: 1929
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €7.957b
  • Shares outstanding: 82.50m
  • Website:

Number of Employees


  • Ipsen S.A.
  • 65 Quai Georges Gorse
  • Cedex
  • Boulogne-Billancourt
  • Ile-de-France
  • 92100
  • France


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/25 00:00
End of Day Share Price2022/05/25 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.